150 related articles for article (PubMed ID: 6611198)
1. Synergistic inhibition of leukemia L1210 cell growth in vitro by combinations of 2-fluoroadenine nucleosides and hydroxyurea or 2,3-dihydro-1H-pyrazole[2,3-a]imidazole.
Sato A; Montgomery JA; Cory JG
Cancer Res; 1984 Aug; 44(8):3286-90. PubMed ID: 6611198
[TBL] [Abstract][Full Text] [Related]
2. Effects of combinations of drugs having different modes of action at the ribonucleotide reductase site on growth of L1210 cells in culture.
Sato A; Carter GL; Bacon PE; Cory JG
Cancer Res; 1982 Nov; 42(11):4353-7. PubMed ID: 6751522
[TBL] [Abstract][Full Text] [Related]
3. Leukemia L1210 cell lines resistant to ribonucleotide reductase inhibitors.
Cory JG; Carter GL
Cancer Res; 1988 Feb; 48(4):839-43. PubMed ID: 3276399
[TBL] [Abstract][Full Text] [Related]
4. Comparison of the actions of 9-beta-D-arabinofuranosyl-2-fluoroadenine and 9-beta-D-arabinofuranosyladenine on target enzymes from mouse tumor cells.
White EL; Shaddix SC; Brockman RW; Bennett LL
Cancer Res; 1982 Jun; 42(6):2260-4. PubMed ID: 7042080
[TBL] [Abstract][Full Text] [Related]
5. Metabolism and chemotherapeutic activity of 9-beta-D-arabinofuranosyl-2-fluoroadenine against murine leukemia L1210 and evidence for its phosphorylation by deoxycytidine kinase.
Brockman RW; Cheng YC; Schabel FM; Montgomery JA
Cancer Res; 1980 Oct; 40(10):3610-5. PubMed ID: 6254636
[TBL] [Abstract][Full Text] [Related]
6. The utility of combinations of drugs directed at specific sites of the same target enzyme--ribonucleotide reductase as the model.
Cory JG; Sato A; Carter GL; Bacon PE; Montgomery JA; Brown NC
Adv Enzyme Regul; 1985; 23():181-92. PubMed ID: 3907303
[TBL] [Abstract][Full Text] [Related]
7. Cross-resistance patterns in hydroxyurea-resistant leukemia L1210 cells.
Carter GL; Cory JG
Cancer Res; 1988 Oct; 48(20):5796-9. PubMed ID: 2844392
[TBL] [Abstract][Full Text] [Related]
8. Proposed mechanism of therapeutic selectivity for 9-beta-D-arabinofuranosyl-2-fluoroadenine against murine leukemia based upon lower capacities for transport and phosphorylation in proliferative intestinal epithelium compared to tumor cells.
Barrueco JR; Jacobsen DM; Chang CH; Brockman RW; Sirotnak FM
Cancer Res; 1987 Feb; 47(3):700-6. PubMed ID: 3802076
[TBL] [Abstract][Full Text] [Related]
9. Effects of 2-chloro-9-(2-deoxy-2-fluoro-beta-D-arabinofuranosyl)adenine on K562 cellular metabolism and the inhibition of human ribonucleotide reductase and DNA polymerases by its 5'-triphosphate.
Parker WB; Shaddix SC; Chang CH; White EL; Rose LM; Brockman RW; Shortnacy AT; Montgomery JA; Secrist JA; Bennett LL
Cancer Res; 1991 May; 51(9):2386-94. PubMed ID: 1707752
[TBL] [Abstract][Full Text] [Related]
10. Effects of biochemical modulation of drug combinations directed at the ribonucleotide reductase site on leukemia L1210 cell growth in culture.
Sato A; Carter GL; Bacon PE; Cory JG
Adv Enzyme Regul; 1983; 21():259-70. PubMed ID: 6400064
[TBL] [Abstract][Full Text] [Related]
11. Potentiation of 1-beta-D-arabinofuranosylcytosine metabolism and cytotoxicity by 2,3-dihydro-1H-imidazolo[1,2-b]pyrazole in the human promyelocytic leukemic cell, HL-60.
Grant S; Bhalla K; Rauscher F; Cadman E
Cancer Res; 1983 Nov; 43(11):5093-100. PubMed ID: 6577943
[TBL] [Abstract][Full Text] [Related]
12. Two approaches that increase the activity of analogs of adenine nucleosides in animal cells.
Plunkett W; Cohen SS
Cancer Res; 1975 Jun; 35(6):1547-54. PubMed ID: 1079475
[TBL] [Abstract][Full Text] [Related]
13. Resistance to 9-beta-D-arabinofuranosyladenine in cultured leukemia L 1210 cells.
Cass CE; Selner M; Phillips JR
Cancer Res; 1983 Oct; 43(10):4791-8. PubMed ID: 6603904
[TBL] [Abstract][Full Text] [Related]
14. Resistance to 9-beta-D-arabinofuranosyl-2-fluoroadenine due to reduced incorporation into DNA from competition by excess deoxyadenosine triphosphate: implications for different sensitivities to nucleoside analogues.
Yoshio N; Kawai Y; Hori H; Ueda T
Int J Hematol; 2005 Jun; 81(5):405-12. PubMed ID: 16158821
[TBL] [Abstract][Full Text] [Related]
15. Antineoplastic effect of the combination of 2,3-dihydro-1H-pyrazole[2,3a]imidazole plus deoxyadenosine/erythro-9-(2-hydroxyl-3-nonyl)adenine in mice with L1210 leukemia cells.
Matsumoto M; Weckbecker G; Cory JG
Cancer Commun; 1990; 2(1):1-6. PubMed ID: 2369548
[TBL] [Abstract][Full Text] [Related]
16. In vitro cytotoxic effects of fludarabine (2-F-ara-A) in combination with commonly used antileukemic agents by isobologram analysis.
Kano Y; Akutsu M; Tsunoda S; Suzuki K; Ichikawa A; Furukawa Y; Bai L; Kon K
Leukemia; 2000 Mar; 14(3):379-88. PubMed ID: 10720130
[TBL] [Abstract][Full Text] [Related]
17. Metabolism and therapeutic efficacy of 9-beta-D-arabinofuranosyl-2-fluoroadenine against murine leukemia P388.
Avramis VI; Plunkett W
Cancer Res; 1982 Jul; 42(7):2587-91. PubMed ID: 7083151
[TBL] [Abstract][Full Text] [Related]
18. In vitro biological activity of 9-beta-D-arabinofuranosyl-2-fluoroadenine and the biochemical actions of its triphosphate on DNA polymerases and ribonucleotide reductase from HeLa cells.
Tseng WC; Derse D; Cheng YC; Brockman RW; Bennett LL
Mol Pharmacol; 1982 Mar; 21(2):474-7. PubMed ID: 7048062
[TBL] [Abstract][Full Text] [Related]
19. Increased activation of 1-beta-D-arabinofuranosylcytosine by hydroxyurea in L1210 cells.
Walsh CT; Craig RW; Agarwal RP
Cancer Res; 1980 Sep; 40(9):3286-92. PubMed ID: 7427943
[TBL] [Abstract][Full Text] [Related]
20. Enhancement of the DNA breakage and cytotoxic effects of intercalating agents by treatment with sublethal doses of 1-beta-D-arabinofuranosylcytosine or hydroxyurea in L1210 cells.
Minford J; Kerrigan D; Nichols M; Shackney S; Zwelling LA
Cancer Res; 1984 Dec; 44(12 Pt 1):5583-93. PubMed ID: 6208999
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]